Caryn Lerman

faculty photo
Professor of Psychology in Psychiatry
Mary W. Calkins Professor, Annenberg School for Communication, University of Pennsylvania
Deputy Director, Abramson Cancer Center, University of Pennsylvania
Director, Neuroscience of Behavior Initiative , University of Pennsylvania
Co-Director, Penn Medicine Neuroscience Center, University of Pennsylvania
Department: Psychiatry

Contact information
Center for Interdisciplinary Research on Nicotine Addiction (CIRNA)
3535 Market Street, Suite 4100
Philadelphia, PA 19104
Office: 215-746-7141
Fax: 215-746-7140
Graduate Group Affiliations
Education:
B.S. (Psychology)
Pennsylvania State University , 1981.
M.S. (Psychology)
University of Southern California , 1982.
Ph.D. (Clinical Psychology)
University of Southern California , 1984.
(Internship in Clinical/Medical Psychology)
Boston Veterans Administration Medical Center , 1985.
Permanent link
 

Description of Research Expertise

Dr. Lerman’s research interests focus on translating research in neuroscience, pharmacology, genetics and behavioral science to develop improved interventions for health risk behavior change.

Description of Other Expertise

Teleos Leadership Institute, Certification as Executive Coach

Selected Publications

Wang Z, Faith M, Patterson F, Tang K, Kerrin K, Wileyto EP, Detre JA, Lerman C.: Neural substrates of abstinence-induced cigarette cravings in chronic smokers. Journal of Neuroscience 27: 14030-14040, 2007.

Loughead J, Wileyto EP, Valdez NJ, Sanborn P, Tang K, Strasser AA, Ruparel K, Ray R, Gur RC, Lerman C.: Effect of abstinence challenge on brain function and cognition in smokers differs by COMT genotype. Molecular Psychiatry 14(8): 820-826, 2009.

Schnoll RA, Patterson F, Wileyto EP, Heitjan D, Shields AE, Asch D, Lerman C. : Effectiveness of extended duration transdermal nicotine therapy: a randomized trial. Annals of Internal Medicine 152(3): 144-151, 2010.

Loughead J, Ray R, Wileyto EP, Ruparel K, Sanborn P, Siegel S, Gur RC, Lerman C.: Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers. Biological Psychiatry 67(8): 715-721, 2010.

Lerman C, Jepson C, Wileyto EP, Patterson F, Schnoll R, Mroziewicz M, Benowitz N, Tyndale RF.: Genetic variation in nicotine metabolism predicts the efficacy of extended duration transdermal nicotine therapy. Clinical Pharmacology & Therapeutics 87(5): 553-557, 2010.

Mrazek DA, Lerman C. : Pharmacogenomics: facilitating clinical implementation. Journal of the American Medical Association 306(3): 304-305, 2011.

Lerman C, Schnoll, RA, Hawk LW, Cinciripini P, George TP, Wileyto EP, Swan GE, Benowitz NI, Heitjan DF, Tyndale RF, PGRN-PNAT Research Group.: Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. The Lancet Respiratory Medicine S2213-2600(14): 70294-70292, 2015.

Loughead J, Wileyto EP, Ruparel K, Falcone M, Hopson R, Gur R, Lerman C. : Working memory-related neural activity predicts future smoking relapse. Neuropsychopharmacology 40(6): 1311-1320, 2015.

Ray R, Ruparel K, Newberg A, Wileyto EP, Loughead J, Divgi C, Blendy JA, Logan J, Zubieta JK, Lerman C. : Human mu opioid receptor (OPRM1 A118G) polymorphism is associated with brain mu opiod receptor binding potential in smokers. Proceedings of the National Academy of Sciences USA 108(22): 9268-9273, 2011.

back to top
Last updated: 07/29/2015
The Trustees of the University of Pennsylvania